Skip to main content

Advertisement

SpringerLink
Log in

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

Abbreviations

PPI:

Proton pump inhibitor

CYP2C19:

Cytochrome P450 2C19

GERD:

Gastroesophageal reflux disease

H. Pylori :

Helicobacter pylori

AUC:

Area under the serum concentration vs time curve

NM:

Normal metabolizer

IM:

Intermediate metabolizer

PM:

Poor metabolizer

UM:

Ultra-rapid metabolizer

RM:

Rapid metabolizer

PGx:

Pharmacogenomics

References

  1. Lima JJ, Thomas CD, Barbarino J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.2015.

    Article  PubMed  Google Scholar 

  2. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528–534

    Article  Google Scholar 

  3. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol. 2001;13:S43-47

    PubMed  Google Scholar 

  4. Dean L. Esomeprazole Therapy and CYP2C19 Genotype. 2012 Oct 1 [Updated 2019 Sep 23]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda MD: National Center for Biotechnology Information (US); 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100896/.

  5. Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334–344

    Article  Google Scholar 

  6. Adam T, Aliferis CF. Personalized and precision medicine informatics: a workflow-based view. Cham: Springer; 2020.

    Book  Google Scholar 

  7. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genom. 2010;4:278–281

    Article  CAS  Google Scholar 

  8. Scott SA, Sangkuhl K, Shuldiner AR et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genom. 2012;22:159–165

    Article  CAS  Google Scholar 

  9. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526

    Article  CAS  Google Scholar 

  10. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95:2–8

    Article  CAS  Google Scholar 

  11. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65:437–439

    Article  CAS  Google Scholar 

  12. Payan M, Rouini MR, Tajik N, Ghahremani MH, Tahvilian R. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population. Daru 2014;22:81

    Article  Google Scholar 

  13. Baldwin RM, Ohlsson S, Pedersen RS et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008;65:767–774

    Article  CAS  Google Scholar 

  14. Gumus E, Karaca O, Babaoglu MO et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol. 2012;68:629–636

    Article  CAS  Google Scholar 

  15. Franciosi JP, Mougey EB, Williams A et al. Association between CYP2C19*17 alleles and pH probe testing outcomes in children with symptomatic gastroesophageal reflux. J Clin Pharmacol. 2018;58:89–96

    Article  CAS  Google Scholar 

  16. Deshpande N, Sharanya V, Ravi Kanth V et al. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene 2016;9:159–164

    Article  Google Scholar 

  17. Hunfeld NG, Mathot RA, Touw DJ et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65:752–760

    Article  CAS  Google Scholar 

  18. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447–460

    Article  Google Scholar 

  19. Saito Y, Serizawa H, Kato Y et al. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol. 2015;21:13548–13554

    Article  CAS  Google Scholar 

  20. Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: Evidence for a differential effect. Drug Metab Dispos. 2010;38:894–897

    Article  CAS  Google Scholar 

  21. Franciosi JP, Mougey EB, Williams A et al. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. Eur J Pediatr. 2018;177:69–77

    Article  CAS  Google Scholar 

  22. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis. In Proceedings of the AGREE Conference. Gastroenterology. 2018 vol 155, pp. 1022–1033 e1010.

  23. Mougey EB, Williams A, Coyne AJK et al. CYP2C19 and STAT6 variants influence the outcome of proton pump inhibitor therapy in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2019;69:581–587

    Article  CAS  Google Scholar 

  24. Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics 2019;13:39

    Article  Google Scholar 

  25. Pratt VM, Del Tredici AL, Hachad H et al. Recommendations for Clinical CYP2C19 genotyping allele selection: A report of the association for molecular pathology. J Mol Diagn. 2018;20:269–276

    Article  CAS  Google Scholar 

  26. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–350

    Article  CAS  Google Scholar 

  27. Pulley JM, Denny JC, Peterson JF et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012;92:87–95

    Article  CAS  Google Scholar 

  28. Bielinski SJ, St Sauver JL, Olson JE et al. Cohort profile: the right drug, right dose, right time: Using genomic data to individualize treatment protocol (RIGHT protocol). Int J Epidemiol. 2020;49:23–24k

    Article  Google Scholar 

  29. Pereira NL, Farkouh ME, So D et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA 2020;324:761–771

    Article  CAS  Google Scholar 

  30. Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019;9:40

    Article  Google Scholar 

  31. Moyer AM, Caraballo PJ. The challenges of implementing pharmacogenomic testing in the clinic. Expert Rev Pharmacoecon Outcomes Res. 2017;17:567–577

    Article  Google Scholar 

  32. Swen JJ. Pharmacogenetics: from bench to byte--an update of guidelines www.pharmgkb.org. Published 2011. Accessed.

  33. Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73:1967–1976

    Article  Google Scholar 

  34. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-808 e807

    Article  CAS  Google Scholar 

  35. Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019;21:1224–1232

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA

    Dana M. Harris, Fernando F. Stancampiano & Jose R. Valery

  2. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA

    Yan Bi

  3. Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA

    M. Caroline Burton

  4. Department of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA

    Ann M. Moyer

  5. Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA

    Michael J. Schuh

Authors
  1. Dana M. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando F. Stancampiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Caroline Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ann M. Moyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael J. Schuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jose R. Valery
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yan Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

D.H. contributed to conception, writing. F.S.,Y.B. and A.M. were involved in supervision, editing. M.C.B. and J.R.V. contributed to editing. M.S. was involved in writing, editing. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dana M. Harris.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harris, D.M., Stancampiano, F.F., Burton, M.C. et al. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice. Dig Dis Sci 66, 4120–4127 (2021). https://doi.org/10.1007/s10620-020-06814-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06814-1

Keywords

Search

Navigation